vasamed Previews AcQtrac(TM) ICG System to Medical Community Worldwide Noninvasive Hemodynamic Assessment System Delivers Solution for $2B Cardiac Output Market MINNEAPOLIS, April 7 /PRNewswire-FirstCall/ -- vasamed (OTC:OPTL) (BULLETIN BOARD: OPTL) a leader in non-invasive, hemodynamic assessment technology, previewed its AcQtrac(TM) Impedance Cardiography System to physicians at March 2005 meetings of the American College of Cardiology (ACC) held in Orlando, Florida and the International Symposium on Intensive Care and Emergency Medicine (ISICEM) held in Brussels, Belgium. "The introduction of our patented Cardiac Amplifier Technology will make true diagnostic ICG available for the first time and enhance the viability of non invasive hemodynamic assessment across the broadest range of patient types. AcQtrac ICG tells the mechanical contraction story of the heart, providing parameters such as cardiac output, thoracic fluid volume and systemic vascular resistance. Knowing these parameters in the office can mean earlier diagnosis which can lead to earlier treatment and the potential delay in the onset of some symptoms," said Terry Duesterhoeft, vice president Sales & Marketing of vasamed. "In-office testing with AcQtrac ICG also allows the doctor to potentially use the results from diagnostic tests to determine the severity of the heart problem, how best to treat a condition and to decide if a treatment is effective." According to Duesterhoeft, "AcQtrac ICG can improve the accessibility of important Cardio-Vascular Disease testing right in the physicians' office or any point-of-care location where Cardio-Vascular information could be useful." "AcQtrac has the ability to expand cardiac output monitoring to patients currently not monitored with much more than a medical history, blood pressure and pulse rate," said Paulita LaPlante, President and CEO at vasamed. "This product marks another milestone in fulfilling our commitment to provide Non- Invasive Hemodynamic Assessment tools to the medical marketplace and address cardiovascular disease, the number one killer of men and women in the United States." vasamed(TM) designs, licenses, manufactures and distributes products that can be used by your doctor -- right in the office -- to tell him/her whether your heart and blood vessels are healthy. vasamed's products and technology include SensiLase(TM) Microvascular Assessment System to measure Skin Perfusion Pressure (SPP), AcQtrac(TM) Impedance Cardiography (ICG) to monitor heart function and Tissue Carbon Dioxide Technologies, including CapnoProbe(TM), to monitor tissue wellness. For more information about vasamed technology and services and new products, see the company's web site at http://www.vasamed.com/ . DATASOURCE: vasamed CONTACT: Wes Peterson, CFO, of vasamed, +1-952-944-5857, ext. 542 Web site: http://www.vasamed.com/

Copyright